Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis

Targeted Oncology

Volumn 11, Issue 6, 2016, Pages 753-761

  Li, Xue ^a,b   Li, Minghuan ^b   Lian, Zhen ^a   Zhu, Hui ^b   Kong, Li ^b   Wang, Ping ^a   Yu, Jinming ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; GENE EXPRESSION; HUMAN; LYMPH VESSEL METASTASIS; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PD L1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW; BREAST TUMOR; GENETICS; META ANALYSIS; METABOLISM; PROGNOSIS;

BREAST NEOPLASMS; HUMANS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84978790778     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-016-0451-8     Document Type: Review

References (48)

1. Pennock GK, Chow LQ. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. 2015;20:812–22.
2. Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T cells: how do they suppress immune responses? Int Immunol. 2009;21:1105–11.
3. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.
4. Flies DB, Sandler BJ, Sznol M, et al. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med. 2011;84:409–21.
5. Whiteside TL. The role of death receptor ligands in shaping tumor microenvironment. Immunol Investig. 2007;36:25–46.
6. Sharabi AB, Lim M, Deweese TL, et al. Radiation and checkpoint blockade immunotherapy: radiosensitization and potential mechanisms of synergy. Lancet Oncol. 2015;16(13):e498–509.
7. La-Beck NM, Jean GW, Huynh C, et al. Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy. 2015;35:963–76.
8. Ghasemzadeh A, Bivalacqua TJ, Hahn NM, et al. New strategies in bladder cancer: a second coming for immunotherapy. Clin Cancer Res. 2016;22:793–801.
9. Chen J, Jiang CC, Jin L, et al. Regulation of PD-L1: a novel role of pro-survival signaling in cancer. Ann Oncol. 2016;27:409–16.
10. Ali OA, Lewin SA, Dranoff G, et al. Vaccines combined with immune checkpoint antibodies promote cytotoxic T cell activity and tumor eradication. Cancer Immunol Res. 2016;4:95–100.
11. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2015;515:563–7.
12. Reiss KA, Forde PM, Brahmer JR. Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy. 2014;6:459–75.
13. Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23:2965–70.
14. Zhong A, Xing Y, Pan X, et al. Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis. Onco Targets Ther. 2015;8:3595–601.
15. Prall F, Huhns M. PD-L1 expression in tumor buds of colorectal carcinoma. Histopathology. 2016;69:158–60.
16. Liu J, Liu Y, Wang W, et al. Expression of immune checkpoint molecules in endometrial carcinoma. Exp Ther Med. 2015;10:1947–52.
17. Berretta M, Stanzione B, Di Francia R, et al. The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology. Eur Rev Med Pharmacol Sci. 2015;19:4207–9.
18. Weinstock M, Mcdermott D. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol. 2015;7:365–77.
19. Thoma C. Prostate cancer: PD-L1 expression is common and indicates poor prognosis. Nat Rev Urol. 2016;13:5.
20. Marquez-Rodas I, Cerezuela P, Soria A, et al. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med. 2015;3:267.
21. Qin T, Zeng YD, Qin G, et al. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget. 2015;6:33972–81.
22. Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014;146:15–24.
23. Baptista MZ, Sarian LO, Derchain SF, et al. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol. 2016;47:78–84.
24. Schalper KA, Velcheti V, Carvajal D, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20:2773–82.
25. Sabatier R, Finetti P, Mamessier E, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015;6:5449–64.
26. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–69. W64.
27. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65–94.
28. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014;12:1500–24.
29. Zeng LN, Zhang LL, Shi J, et al. The primary microbial pathogens associated with premature rupture of the membranes in China: a systematic review. Taiwan J Obstet Gynecol. 2014;53:443–51.
30. Malhamé I, Cormier M, Sugarman J, Schwartzman K. Latent tuberculosis in pregnancy: a systematic review. PLoS One. 2016;11, e0154825.
31. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
32. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.
33. Mahoney KM, Freeman GJ, Mcdermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther. 2015;37:764–82.
34. Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016.
35. Dirix LY, Takacs I, Nikolinakos P, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2015 Dec 6–10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr S1-04.
36. Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triplenegative breast cancer (TNBC) [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18–22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2859.
37. Rizvi N, Shepherd F, Antonia S, et al. First-line monotherapy with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-L1 status. J Radiat Oncol Biol Phys. 2014;90:S31.
38. Luis P, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab versus docetaxel in advanced non-squamous (non-SQ) cell non-small cell lung cancer (NSCLC). J Clin Oncol. 2015; 33(suppl), abstract LBA109.
39. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.
40. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an antiPD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257–65.
41. Ali HR, Glont SE, Blows FM, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015;26:1488–93.
42. Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006;8:190–8.
43. Lastwika KJ, Wrd W, Li QK, et al. Control of PD-L1 expression by oncogenic activation of the AKT/mTOR pathway in non-small cell lung cancer. Cancer Res. 2016;76:227–38.
44. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;17:3268–77.
45. Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355–63.
46. Crane CA, Panner A, Murray JC, et al. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene. 2009;28:306–12.
47. Bordeaux JM, Cheng H, Welsh AW, et al. Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen. PLoS One. 2012;7, e36559.
48. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig. 2014;9:107–16.